Otezla quality of life data for Psoriasis patients from ESTEEM trials- Celgene

Celgene International S�rl, announced that patient-reported health outcomes data for Otezla (apremilast) for moderate to severe Psoriasis, were presented at the 23rd European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam . The analyses from the Phase III ESTEEM clinical trial program assessed the effect of apremilast on health-related quality of life measures and on work productivity/work limitation. A new analysis of the ESTEEM 2 trial demonstrated that treatment with apremilast 30 mg twice daily after 16 weeks significantly improved health-related quality of life compared with placebo. Significant improvement was seen in a variety of these standardized measures, including the Dermatology Quality of Life Index (DLQI), the Patient Health Questionnaire, the European Quality of Life 5 Dimensions Questionnaire and the Short-Form Health Survey mental component summary and physical component summary.

At Week 16, more than 70 percent of patients who received apremilast 30 mg twice daily achieved clinically meaningful improvement in DLQI of at least 5-points. Approximately half of patients treated with apremilast 30 mg twice daily also achieved at least a 50 percent improvement from baseline in the PASI -50 score versus placebo, along with a 5-point or greater DLQI improvement, thereby meeting treatment goal criteria from National Institute for Health and Care Excellence (NICE) and European S3 guidelines.